Key Highlights

  • Amgen closed up 4.57% at $407.83 on August 5, following Tuesday's earnings report.
  • Second-quarter revenue reached $10.05 billion, beating consensus estimates of $9.43 billion.
  • Adjusted EPS of $6.29 beat the consensus estimate of $5.62.
  • Growth was broad-based, led by Repatha, up 37%, and EVENITY, up 38%.
  • Management raised full-year 2026 guidance, prompting a wave of analyst price target increases from firms including TD Cowen, BMO Capital, and Scotiabank.

What Happened

Amgen (NASDAQ:AMGN) is a leading global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California, dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. Its extensive product portfolio spans oncology and hematology, inflammatory diseases, bone health, cardiovascular disease, nephrology, and neuroscience, featuring well-known brands such as Enbrel, Prolia, Otezla, Repatha, XGEVA, Neulasta, KYPROLIS, and BLINCYTO.

Shares surged more than 4.5% on August 5 following a strong second-quarter earnings beat reported after Tuesday's close. Adjusted EPS of $6.29 topped consensus estimates of $5.62, and revenue of $10.05 billion beat the $9.43 billion estimate. Growth was broad-based, led by Repatha, up 37%, EVENITY, up 38%, and continued strength in the company's rare-disease and oncology franchises.

Analyst Reaction and Guidance Raise

The results prompted a wave of price target increases, including from TD Cowen, Oppenheimer, BMO Capital, and UBS, as analysts maintained bullish ratings citing strength across the diversified portfolio. Management raised full-year 2026 guidance to $38.2 billion to $39.4 billion in revenue and non-GAAP EPS of $22.30 to $23.50, supported by continued momentum from the company's six key growth drivers, Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars, which collectively grew 26% year-over-year and represented nearly 70% of total product sales.

Twenty-two products delivered double-digit sales growth during the quarter, with 17 products now annualizing at more than $1 billion in sales. TEZSPIRE sales rose 42% to $486 million, UPLIZNA sales increased 90% to $335 million, and IMDELLTRA sales grew 115%, establishing itself as a leading treatment for small cell lung cancer with expanding adoption. The company's biosimilars portfolio also grew 29% year-over-year, with PAVBLU sales up 121%, helping offset declines in legacy bone-health products Prolia and XGEVA, which fell a combined 33% due to biosimilar competition.

The stock's rally also comes as the broader S&P 500 and Nasdaq trade near record highs this week on strong tech earnings, while investors continue to weigh the pressure on legacy products against the company's expanding oncology and cardiometabolic pipeline, including MariTide, which is advancing through nine ongoing and planned Phase 3 studies in obesity.

Conclusion

Amgen's broad-based beat and raised guidance reinforce the durability of its diversified product portfolio even as legacy products face growing biosimilar competition. With a wave of analyst price target increases following the print, the stock's close near 52-week highs on August 5 reflects renewed investor confidence in the company's ability to sustain growth through its expanding late-stage pipeline.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.